The Oncologist’s Impact on Drug Choices

Restricted access

George N. Whitelaw, RPh, is President of SMT Inc., a New Jersey-based firm that develops strategies and tactics for pharmaceutical companies in response to emerging health care policy initiatives. A registered pharmacist in the state of New York, Mr. Whitelaw’s educational accomplishments include a BS from St. John’s College of Pharmacy and graduate credits at the Wharton School of Business. Mr. Whitelaw has worked in the health care industry for more than 30 years, honing his skills in the public and private policy arenas. He is a guest lecturer at medical and pharmacy societies, hospital associations, and business schools.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

Kay E. Jewell, MD, is a consultant to the health care industry, and serves as Chief Medical Officer for SMT, Inc. Her work focuses on the link between quality, quality measures, and patient care. Dr. Jewell received her degree from the University of Wisconsin Medical School. She completed internal medicine residency and fellowship training in psychiatry and geriatrics, and extensive graduate course work at UW-Madison in Administrative Medicine and at UW-SP in Health and Wellness.

She has worked in quality and safety issues at the state and national levels for 32 years with nursing homes, home health, hospice, hospitals, and physicians. She was the first Medical Director for Medicare Part B in Wisconsin and then served as Medical Officer at CMS in operations and policy. She is Vice Chair of the Wisconsin Medical Society Quality Council & member of the AMA-PCPI. Her current work focuses on education of healthcare providers, pharmaceutical companies, and the public on quality and patient safety performance improvement; analysis of clinical conditions, guidelines, and identification of gaps in measures; and the active participation of consumers, physicians, and others in the development process.

Nevin Whitelaw is Vice President of SMT Inc., a New Jersey–based firm that develops strategies and tactics for pharmaceutical companies in response to emerging healthcare policy initiatives.

Mr. Whitelaw has a BA from DePauw University with a major in Economics. He has led retrospective and prospective studies to achieve patient access and medical treatment options. Recent studies include the application of large insurance files to develop opportunities to improve the efficiency in the provision of care while supporting patient safety and quality.

  • 1

    United States General Accounting Office. Off-label drugs, reimbursement policies constrain physicians in their choice of cancer therapies (report GAO/PEMD-91-14). September 1991. Washington DC. Available at: Last accessed October 18, 2012.

    • Search Google Scholar
    • Export Citation
  • 2

    Abernathy AP, Balk E, Hammond JM. Compendia for coverage of off-label uses of drugs and biologics in an anticancer chemotherapeutic regimen. AHRQ Technology Assessment. Published May 7, 2007. Available at: Last accessed October 13, 2012.

    • Search Google Scholar
    • Export Citation
  • 3

    Peppercorn J, Burstein H, Miller FG. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol 2008;26:59946000.

    • Search Google Scholar
    • Export Citation
  • 4

    Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997:90;42434251.

  • 5

    Medicare. Compendia as Authoritative Sources for Use in the Determination of a ‘Medically Accepted Indication’ of Drugs and Biological Used Off-Label in an Anti-cancer Chemotherapeutic Regimen. MLN Matters. Number MM6191. Published November 25, 2008. Available at: Last accessed October 13, 2012.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 65 53 0
PDF Downloads 7 4 0
EPUB Downloads 0 0 0